4000-520-616
欢迎来到免疫在线!(蚂蚁淘生物旗下平台)  请登录 |  免费注册 |  询价篮
主营:主营:分子类,蛋白类,抗体类,生化类试剂
咨询热线电话
4000-520-616
当前位置: 首页 > 产品中心 > juhewu > Selleck Chemicals/Temsiromus(CCI-779)/S1044
商品详细Selleck Chemicals/Temsiromus(CCI-779)/S1044
Selleck Chemicals/Temsiromus(CCI-779)/S1044
Selleck Chemicals/Temsiromus(CCI-779)/S1044
商品编号: S1044
品牌: Selleck Chemicals
市场价: ¥17400.00
美元价: 10440.00
产地: 美国(厂家直采)
公司:
产品分类: 聚合物
公司分类: juhewu
联系Q Q: 3392242852
电话号码: 4000-520-616
电子邮箱: info@ebiomall.com
商品介绍
DescriptionTemsirolimus (CCI-779, NSC 683864) is a specific mTOR inhibitor with IC50 of 1.76 μM in a cell-free assay. Temsirolimus induces autophagy and apoptosis.
Targets
mTOR [1](Cell-free assay)
1.76 μM
In vitro

In the absence of FKBP12, Temsirolimus potently inhibits mTOR kinase activity with IC50 of 1.76 μM, similar to that of rapamycin with IC50 of 1.74 μM. Temsirolimus treatment at nanomolar concentrations (10 nM to <5 μm)="" displays="" a="" modest="" and="" selective="" antiproliferative="" activity="" via="" fkbp12-dependent="" mechanism,="" but="" can="" completely="" inhibit="" the="" proliferation="" of="" a="" broad="" panel="" of="" tumor="" cells="" at="" low="" micromolar="" concentrations="" (5-15="" μm),="" involving="" fkbp12-independent="" suppression="" of="" mtor="" signaling.="" temsirolimus="" treatment="" at="" micromolar="" but="" not="" nanomolar="" concentrations="" (20="" μm)="" causes="" a="" marked="" decline="" in="" global="" protein="" synthesis="" and="" disassembly="" of="" polyribosomes,="" accompanied="" by="" rapid="" increase="" in="" the="" phosphorylation="" of="" translation="" elongation="" factor="" eef2="" and="" the="" translation="" initiation="" factor="" eif2a.="">[1] Temsirolimus inhibits the phosphorylation of ribosomal protein S6, more potently in PTEN-positive DU145 cells than in PTEN-negative PC-3 cells, and inhibits cell growth and clonogenic survival of both cells in a concentration-dependent manner. [2] Temsirolimus (100 ng/mL) potently inhibits proliferation and induces apoptosis in primary human lymphoblastic leukemia (ALL) cells. [3]

Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
human HSC-4 cellNIC4botIem:5dHigbY5pcWKrdHnvckBie3OjeR?=NYDkdW9TUW6qaXLpeIlwdiCxZjDoeY1idiCKU1OtOEBkWyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOTF|IH7NM1jzSXNCVkeHUh?=
human L-363 cellMljYS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?MUnJcohq[mm2aX;uJI9nKGi3bXHuJGwuOzZ|IHPlcIwh3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6yOFIhdk1?NGLJcZRUSU6JRWK=
human Ramos-2G6-4C10 cellNGjR[I1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=MmjLTY5pcWKrdHnvckBwiCqdX3hckBT[W2xcz2yS|YuPENzMDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuN|QzKG6PM2rXWHNCVkeHUh?=
human SBC-1 cellNUPKRW1jT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm=NV7CZnNWUW6qaXLpeIlwdiCxZjDoeY1idiCVQlOtNUBkWyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPDR2IH7NNYj4PFlCW0GQR1XS
human MHH-PREB-1 cellMkLES5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?M3TKNWlvcGmkaYTpc44hd2ZiaIXtZY4hVUiKLWDSSWIuOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwNEm1JI5OM{Hj[XNCVkeHUh?=
human LNCAP cellsM4PpXnBzd2yrZnXyZZRqd25iYYPzZZk>MVyzJIRigXN?NIDSc5dCdnSrcILvcIlnXKjdHn2[UBi[3Srdnn0fUBi2GrboP0JIh2dWGwIFzOR2FRKGOnbHzzJIFnfGW{IEOg[IF6eyCkeTDNWHMh[XO|YYmsJGlEPTB;MD61JI5OMlfrNlE1Ozh3N{m=
human HH cellMnHJS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?NF3qRYNKdmirYnn0bY9vKG:oIHj1cYFvKEiKIHPlcIwh3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD62OlQhdk1?MVfTRW5ITVJ?
human TYK-nu cellMkPLS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?MlTPTY5pcWKrdHnvckBwiCqdX3hckBVYUtvboWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlc4QCCwTR?=NGT6[ZhUSU6JRWK=
human H4 cellNUizZ3ByT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm=M1PrPWlvcGmkaYTpc44hd2ZiaIXtZY4hUDRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLkC3JI5OMVPTRW5ITVJ?
human K5 cellNFvZXHVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=MX7Jcohq[mm2aX;uJI9nKGi3bXHuJGs2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS5|MzDuUS=>MkX0V2FPT0WU
human PA-1 cellMYnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?MWjJcohq[mm2aX;uJI9nKGi3bXHuJHBCNTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLkS3JI5OM{XsUHNCVkeHUh?=
human SK-NEP-1 cellMULHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?NGjBXndKdmirYnn0bY9vKG:oIHj1cYFvKFONLV7FVE0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS52OTDuUS=>MnnMV2FPT0WU
human 697 cellNXX6VnZTT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm=NUfNVINLUW6qaXLpeIlwdiCxZjDoeY1idiB4OUegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlchdk1?NHfvcIZUSU6JRWK=
human CTB-1 cellMUHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?MmO1TY5pcWKrdHnvckBwiCqdX3hckBEXEJvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuPVMhdk1?NYjKb4JXW0GQR1XS
human DB cellMlfwS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?NWP0V|dGUW6qaXLpeIlwdiCxZjDoeY1idiCGQjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuNVIhdk1?NEKxPVNUSU6JRWK=
human MLMA cellNUO0N5NrT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm=NVfJR5A{UW6qaXLpeIlwdiCxZjDoeY1idiCPTF3BJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{4{OSCwTR?=MoTpV2FPT0WU
human GAMG cellNGDpe4tIem:5dHigbY5pcWKrdHnvckBie3OjeR?=MmfqTY5pcWKrdHnvckBwiCqdX3hckBISU2JIHPlcIwh3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mz64NkBvVQ>?NVrrbY9NW0GQR1XS
human JVM-3 cellMV3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?M3LMdWlvcGmkaYTpc44hd2ZiaIXtZY4hUl[PLUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlk2KG6PMmjHV2FPT0WU
human LAMA-84 cellNFzaWoxIem:5dHigbY5pcWKrdHnvckBie3OjeR?=M2TNR2lvcGmkaYTpc44hd2ZiaIXtZY4hVEGPQT24OEBkWyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvODNibl2=NVLGbIVSW0GQR1XS
human RPMI-8226 cellNHS3OopIem:5dHigbY5pcWKrdHnvckBie3OjeR?=Mn2zTY5pcWKrdHnvckBwiCqdX3hckBTWE2LLUiyNlYh[2WubDDndo94fGhiaX6gZUBkWyuIIpZYJqdGm2eTDhd5NigSxiSVO1NF01NjF3IH7NNVKV2trW0GQR1XS
human MOLT-4 cellNHvvWVVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=M2nIPGlvcGmkaYTpc44hd2ZiaIXtZY4hVU:OVD20JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE4{OSCwTR?=NIfsZ3hUSU6JRWK=
human CAMA-1 cellNGL5dnRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=MXHJcohq[mm2aX;uJI9nKGi3bXHuJGNCVUFvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUSuO|chdk1?MmDwV2FPT0WU
human NCI-SNU-1 cellNUe0cHNHT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm=NF1R3ZKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3TUnUuOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTRwOEGgcm0>NFG0WpNUSU6JRWK=
human SW780 cellNVr5TZp3T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm=NVnpO4FqUW6qaXLpeIlwdiCxZjDoeY1idiCVV{e4NEBkWyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvQDNibl2=MVrTRW5ITVJ?
human H9 cellNED3eo5Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=NF7wbpVKdmirYnn0bY9vKG:oIHj1cYFvKEh7IHPlcIwh3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;ND64PEBvVQ>?NIrKW|FUSU6JRWK=
human BE-13 cellM3;Tc2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7NH;De5hKdmirYnn0bY9vKG:oIHj1cYFvKEKHLUGzJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE46OSCwTR?=MXLTRW5ITVJ?
human ES8 cellM2CzN2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7MVfJcohq[mm2aX;uJI9nKGi3bXHuJGVUQCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTVwMkegcm0>NFLi[XVUSU6JRWK=
human DEL cellMkD3S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?MXvJcohq[mm2aX;uJI9nKGi3bXHuJGRGVCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTVwNE[gcm0>NFz6epNUSU6JRWK=
human QIMR-WIL cellNIj0NodIem:5dHigbY5pcWKrdHnvckBie3OjeR?=NYMUphxUW6qaXLpeIlwdiCxZjDoeY1idiCTSV3SMXdKVCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTVwN{Ggcm0>NUHmdIJzW0GQR1XS
human CGTH-W-1 cellMn7pS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?MUTJcohq[mm2aX;uJI9nKGi3bXHuJGNIXEhvVz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU44PSCwTR?=M{HYO3NCVkeHUh?=
human CHL-1 cellMlPS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?NVPG[WxzUW6qaXLpeIlwdiCxZjDoeY1idiCFSFytNUBkWyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvQDZibl2=M4TFW3NCVkeHUh?=
human A2780 cellNVvU[|B6T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm=MWJcohq[mm2aX;uJI9nKGi3bXHuJGEzPzhyIHPlcIwh3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NT64PEBvVQ>?NUfI[FV{W0GQR1XS
human VA-ES-BJ cellMoHKS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?NULtRXhNUW6qaXLpeIlwdiCxZjDoeY1idiCYQT3FV{1DUiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTVwOTDuUS=>NEPTWWNUSU6JRWK=
human BB65-RCC cellMYHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?MmW4TY5pcWKrdHnvckBwiCqdX3hckBDSjZ3LWLDR{BkWyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVchdk1?NYkSmlGW0GQR1XS
human D-566MG cellM1rhTGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7M1jRSGlvcGmkaYTpc44hd2ZiaIXtZY4hTC13NkNS{BkWyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVcvOTZibl2=MVvTRW5ITVJ?
human MDA468 cellsNUjDOFlCWHKxbHnm[ZJifGmxbjDhd5NigQ>?NXLCe2JGOyCmYYnzM3vrUWFvfGmycn;sbYZmemG2aYlJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVTBOFY5KGOnbHzzJIFnfGW{IEOg[IF6eyCkeTDNWHMh[XO|YYmsJGlEPTB;ODDuUS=>M4r6R|IyPDN6NUe5
human HO-1-N-1 cellM1jhOWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7M3PNOmlvcGmkaYTpc44hd2ZiaIXtZY4hUE9vMT3OMVEh[2WubDDndo94fGhiaX6gZUBkWyuIIpZYJqdGm2eTDhd5Nige,:jDDJR|UxRThwMjDuUS=>NYPFXFJUW0GQR1XS
human RS4-11 cellNUXDOlhZT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm=MYTJcohq[mm2aX;uJI9nKGi3bXHuJHJUPC1zMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUiuOFUhdk1?M1Hwe3NCVkeHUh?=
human PC-3 cellNV7Fc3k2T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm=MYnJcohq[mm2aX;uJI9nKGi3bXHuJHBENTNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD17LkG0JI5OMVXTRW5ITVJ?
human NB69 cellMkfmS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?M17wNGlvcGmkaYTpc44hd2ZiaIXtZY4hVkJ4OTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUmuOFYhdk1?NXBWJZDW0GQR1XS
human HGC-27 cellMWXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?NEXhcY5KdmirYnn0bY9vKG:oIHj1cYFvKEiJQz2yO{BkWyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVkvPiCwTR?=Mkm2V2FPT0WU
human NCI-H720 cellNUfR[Yk1T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm=M3Hs[2lvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVi3NlAh[2WubDDndo94fGhiaX6gZUBkWyuIIpZYJqdGm2eTDhd5NigSxiSVO1NF06NjZ{IH7NMVLTRW5ITVJ?
human NCI-H292 cellMlPhS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?NUf2dlh4UW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFI6OiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTlwOESgcm0>NFHHSZZUSU6JRWK=
human A3-KAW cellMnLZS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?MYLJcohq[mm2aX;uJI9nKGi3bXHuJGE{NUuDVzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGwMlQ{KG6PNH7tfWlUSU6JRWK=
human DU-4475 cellM1WwOWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7MUPJcohq[mm2aX;uJI9nKGi3bXHuJGRWNTR2N{WgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xNU44OyCwTR?=NEfXTGlUSU6JRWK=
human HuH-7 cellNIPqOHNIem:5dHigbY5pcWKrdHnvckBie3OjeR?=MlLTTY5pcWKrdHnvckBwiCqdX3hckBJfUhvNzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGyMlMzKG6PMoL5V2FPT0WU
human J-RT3-T3-5 cellNFP0WI9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=MX7Jcohq[mm2aX;uJI9nKGi3bXHuJGouWlR|LWSzMVUh[2WubDDndo94fGhiaX6gZUBkWyuIIpZYJqdGm2eTDhd5NigSxiSVO1NF0yOi5|ODDuUS=>NF;RVIZUSU6JRWK=
human VM-CUB-1 cellNF;sOWRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=NHXXV45KdmirYnn0bY9vKG:oIHj1cYFvKF[PLVPVRk0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OTJwNkegcm0>M1y1VnNCVkeHUh?=
human MOLT-16 cellM{XkNmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7NEHEToZKdmirYnn0bY9vKG:oIHj1cYFvKE2RTGStNVYh[2WubDDndo94fGhiaX6gZUBkWyuIIpZYJqdGm2eTDhd5NigSxiSVO1NF0yOi56NDDuUS=>MmPHV2FPT0WU
human KG-1 cellM36xOGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7NVfFUnl[UW6qaXLpeIlwdiCxZjDoeY1idiCNRz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVIvQSCwTR?=MVXTRW5ITVJ?
human P12-ICHIKAWA cellNFS5bFBIem:5dHigbY5pcWKrdHnvckBie3OjeR?=M37lRWlvcGmkaYTpc44hd2ZiaIXtZY4hWDF{LVnDTGlMSVeDIHPlcIwh3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUOuNFEhdk1?M1vJc3NCVkeHUh?=
human ACN cellNGHXZ4pIem:5dHigbY5pcWKrdHnvckBie3OjeR?=MmHnTY5pcWKrdHnvckBwiCqdX3hckBCS05iY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zMz6wNkBvVQ>?NWfFR4JPW0GQR1XS
human COLO-684 cellM{ Vmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7MVrJcohq[mm2aX;uJI9nKGi3bXHuJGNQVE9vNki0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVMvOzFibl2=Mnf3V2FPT0WU
human T-24 cellMlzBS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?NF;E[ZdKdmirYnn0bY9vKG:oIHj1cYFvKFRvMkSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xN{45PiCwTR?=M{6PXNCVkeHUh?=
human AGS cellMYLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?M{nqcGlvcGmkaYTpc44hd2ZiaIXtZY4hSUeVIHPlcIwh3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUSuNVEhdk1?NWLpU|hkW0GQR1XS
human EW-13 cellMljMS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?NFnXbo5KdmirYnn0bY9vKG:oIHj1cYFvKEWZLUGzJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVQvPTRibl2=M3TLSXNCVkeHUh?=
human SW962 cellNWTwUGU1T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm=MX;Jcohq[mm2aX;uJI9nKGi3bXHuJHNYQTZ{IHPlcIwh3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUWuOVkhdk1?NXHRfGcxW0GQR1XS
human EW-11 cellMof6S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?M2rGT2lvcGmkaYTpc44hd2ZiaIXtZY4hTVdvMUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xOU43KG6PM4jPcXNCVkeHUh?=
human RXF393 cellM3zCWWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7M1m1dmlvcGmkaYTpc44hd2ZiaIXtZY4hWliIM{mzJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVUvPjZibl2=MmPyV2FPT0WU
human EoL-1-cell cellM{XOTGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7MlXPTY5pcWKrdHnvckBwiCqdX3hckBGd0xvMT3j[YxtKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OTZwMTDuUS=>NYfPeZdEW0GQR1XS

... Click to View More Cell Line Experimental Data

Assay
MethodsTest IndexPMID
Western blot
p-mTOR / mTOR / p-S6 / S6 / p-4E-BP1 / 4E-BP1 ;

PubMed: 23291985

The mTOR inhibitor temsirolimus inhibits the activation of mTOR and its downstream molecules in esophageal cancer cells. Three esophageal cancer cell lines (TE-1, TE-8, and TE-10) were treated with different concentrations of temsirolimus (0–1000nM) and western blot was performed with appropriate antibodies to detect the expression of mTOR and its downstream effectors. β-actin was served as an internal control.

p-rS6 / rS6 / p-AKT /AKT ;

PubMed: 22039466

C,D, Phosphorylation of rS6 (P-rS6) and Akt (P-Akt T308 and P-Akt S473) after treatment with indicated doses of temsirolimus for 72 hrs in temsirolimus-sensitive (C) or temsirolimus-resistant (D) cells was determined by Western blotting. Expression of total rS6 and Akt protein serves as loading controls.

23291985 22039466
Immunofluorescence
NRF2;

PubMed: 22848625

Ectopic expression of Nrf2 (red) and nuclear staining with Dapi (blue) after a 6 hour drug incubation. Yellow numbers represent the percent of cells with nuclear Nrf2 +/− the standard deviation. Scale bar = 10 µM.

22848625
Growth inhibition assay
Cell growth (HGC-3 cells) ;

PubMed: 30866995

Effect of temsirolimus on the growth of HGC-3 and -20 cells in primary culture.

Cell viability ;

PubMed: 22039466

A,B, Endometrial cancer cells were treated with increasing doses of temsirolimus for 72 hrs. Results are separated by (A) sensitivity or (B) resistance as determined by cell viability.

30866995 22039466
In vivoIn the NOD/SCID xenograft models with human ALL, Temsirolimus treatment at 10 mg/kg/day produces a decrease in peripheral blood blasts and in splenomegaly [3] Administration of Temsirolimus (20 mg/kg i.p. 5 days/week) significantly delays the growth of DAOY xenografts by 160% after 1 week and 240% after 2 weeks, compared with controls. Single high-dose of Temsirolimus (100 mg/kg i.p) treatment induces 37% regression of tumor volume within 1 week. Temsirolimus treatment for 2 weeks also delays the growth of rapamycin-resistant U251 xenografts by 148%. [4] Inhibition of mTOR by Temsirolimus improves performance on four different behavioral tasks and decreases aggregate formation in a mouse model of Huntington disease. [5] Administration of Temsirolimus induces significant dose-dependent, antitumor responses against subcutaneous growth of 8226, OPM-2, and U266 xenografts with ED50 of 20 mg/kg and 2 mg/kg for 8226 and OPM-2, respectively, which are associated with inhibited proliferation and angiogenesis, induction of apoptosis, and reduction in tumor cell size. [6]
品牌介绍
Selleck Chemicals是世界领先的高性能的生命科学产品供应商之一,主要致力于提供MAPK和PI3K/Akt/mTOR等上百个信号通路的高特异性小分子抑制剂。Selleck 产品线补充非常及时,可以提供行业内最新的抑制剂类产品。同时Selleck也是专业的高通量筛选抑制剂分子库、API、天然产物和多肽供应商。